Charles Schwab
VOR icon

Charles Schwab’s Vor Biopharma VOR Stock Holding History

Charles Schwab’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
121,398
+99,182
+446% +$1.5M ﹤0.01% 2754
2026
Q1 		$396K Buy
+22,216
New +$313K ﹤0.01% 3176
2024
Q4 		– Sell
-890
Closed -$12.5K – 3520
2024
Q3 		$12.5K Hold
890
– – ﹤0.01% 3499
2024
Q2 		$17.8K Sell
890
-4,306
-83% -$139K ﹤0.01% 3596
2024
Q1 		$246K Hold
5,196
– – ﹤0.01% 3207
2023
Q4 		$234K Hold
5,196
– – ﹤0.01% 3257
2023
Q3 		$220K Hold
5,196
– – ﹤0.01% 3269
2023
Q2 		$321K Buy
5,196
+4,306
+484% +$393K ﹤0.01% 3210
2023
Q1 		$95.7K Buy
890
+346
+64% +$38.3K ﹤0.01% 3254
2022
Q4 		$72.3K Hold
544
– – ﹤0.01% 3300
2022
Q3 		$44K Sell
544
-1,530
-74% -$150K ﹤0.01% 3361
2022
Q2 		$207K Sell
2,074
-2,605
-56% -$267K ﹤0.01% 3240
2022
Q1 		$566K Buy
4,679
+62
+1% +$10.6K ﹤0.01% 3064
2021
Q4 		$1.07M Buy
4,617
+144
+3% +$41.5K ﹤0.01% 2882
2021
Q3 		$1.4M Buy
4,473
+1,021
+30% +$304K ﹤0.01% 2771
2021
Q2 		$1.29M Sell
3,452
-210
-6% -$104K ﹤0.01% 2845
2021
Q1 		$3.16M Buy
+3,662
New +$3.1M ﹤0.01% 2518

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Charles Schwab's VOR Position: Q2 2026 in Review

Charles Schwab increased its Vor Biopharma (VOR) stake by 446% in Q2 2026, buying an estimated $1.5M and bringing the position to 121,398 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

Charles Schwab first reported a position in VOR in Q1 2021 and has held it in 17 quarters since. The position peaked at $3.16M in Q1 2021. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Charles Schwab held 121,398 shares of Vor Biopharma worth $2.23M as of Q2 2026.
  • Charles Schwab bought 99,182 Vor Biopharma shares in Q2 2026, an estimated $1.5M.
  • Vor Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2754 holding.
  • Charles Schwab first reported a position in Vor Biopharma in Q1 2021 and has held it in 17 quarters since.
  • Charles Schwab's Vor Biopharma position peaked at $3.16M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.